Trial reportClinical epigenetics2025
Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.
Trial report in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rare acute myeloid leukemia harboring BCR/ABL1 (P210), AML1-MDS1/EVI1, and AML1/EAP: case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is potentially the only curative option for high-risk acute myeloid leukemia (AML) patients. However, disease relapse remains the principal cause of treatment failure of these patients, and outcomes of salvage treatments are poor. This research seeks to evaluate the efficacy and safety of a dual epigenetic targeting maintenance therapy with chidamide and azacitidine (AZA) in patients with high-risk AML post-allo-HSCT.
methodsThis multicenter, open-label, phase 2 prospective clinical trial (ChiCTR2300067593) recruited and followed up 48 patients diagnosed with high-risk AML post-allo-HSCT from 3 hospitals in China from November 2021 to March 2024. Chidamide (5 mg) was administered orally once daily for 5 days, combined with AZA (75 mg/m
resultsThe 2-year cumulative incidence of relapse (CIR) was 8.4% (95% CI 4.4-12.4%), 2-year relapse-free survival (RFS) was 91.6% (95% CI 87.6-95.6%), and overall survival (OS) was 97.9% (95% CI 95.8-100%). At the end of the follow-up period, 4 patients relapsed, of which 1 patient died of leukemia recurrence; the other three patients underwent second allo-HSCT and are still alive in remission. The most common adverse events (AEs) were hematological toxicity. No grade > 3 AEs were noted. Graft-versus-host disease (GVHD) occurred in 29.2% (14/48) of patients. Six cases (6/48, 12.5%) were complicated with infection. No treatment-related mortality occurred.
conclusionsDual epigenetic targeting maintenance treatment with CHI-AZA has an acceptable toxicity profile and might potentially be effective to prevent relapse in high-risk AML patients after allo-HSCT.
trial registrationClinicalTrials.gov, ChiCTR2300067593. Registered January 12, 2013.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.